Analysts expect Biodel Inc. (NASDAQ:ALBO) to announce earnings per share (EPS) of ($0.87) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Biodel’s earnings. Biodel posted earnings per share of ($0.90) during the same quarter last year, which would indicate a positive year over year growth rate of 3.3%. The firm is expected to report its next quarterly earnings report on Thursday, August 10th.

On average, analysts expect that Biodel will report full year earnings of ($3.81) per share for the current fiscal year, with EPS estimates ranging from ($4.29) to ($3.32). For the next fiscal year, analysts forecast that the firm will report earnings of ($3.07) per share, with EPS estimates ranging from ($3.17) to ($2.97). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover Biodel.

Biodel (NASDAQ:ALBO) last released its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.10) by $0.04.

Separately, Zacks Investment Research upgraded Biodel from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd.

Biodel (NASDAQ ALBO) traded down 3.38% during trading on Thursday, hitting $17.74. The stock had a trading volume of 11,621 shares. Biodel has a 52-week low of $8.55 and a 52-week high of $37.69. The company’s market cap is $111.62 million. The firm’s 50-day moving average price is $19.59 and its 200-day moving average price is $21.11.

Several large investors have recently bought and sold shares of ALBO. Renaissance Technologies LLC boosted its stake in Biodel by 0.5% in the first quarter. Renaissance Technologies LLC now owns 149,632 shares of the biopharmaceutical company’s stock worth $3,591,000 after buying an additional 794 shares during the period. Geode Capital Management LLC boosted its stake in Biodel by 4.5% in the first quarter. Geode Capital Management LLC now owns 13,746 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 588 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Biodel by 4.9% in the first quarter. Vanguard Group Inc. now owns 29,869 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 1,404 shares during the period. Hedge funds and other institutional investors own 12.18% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Biodel Inc. (ALBO) Will Announce Earnings of -$0.87 Per Share” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at

Biodel Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Get a free copy of the Zacks research report on Biodel (ALBO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with's FREE daily email newsletter.